Synthesis and characterization of a new generation of bone-targeting anti-cancer prodrugs

Bone cancers are very hard to treat because of poor blood flow in the bones and drugs to treat bone cancers need to be given at high doses and are often limited by side effects. This project will develop new “prodrugs” designed to target and attach to bones and release a potent anti-cancer drug, regorafenib, directly in the bone tumor. Regorafenib has shown to be active in treating bone cancers, but its use and dose are severely limited by skin and liver side effects. This prodrug will allow more drug to get to the tumor and greatly reduce the exposure to other tissues thus increasing efficacy and mitigating side effects. The technology we develop will be applicable to a whole class of anti-tumor agents.

Faculty Supervisor:

Robert Norman Young

Student:

Partner:

Mesentech Inc

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

Simon Fraser University

Program: